HiFiBiO Therapeutics

HiFiBiO Therapeutics is a clinical-stage global biotech company leveraging its novel high-resolution translational solution, DIS® (Drug Intelligence Science), to optimize the success rate of immunotherapies. By integrating unique single-cell capabilities and AI/ML approaches, using patient samples, HiFiBiO has gained a deep understanding of immune modulation in human diseases, leading to the discovery of novel targets, effective antibody drugs, and predictive biomarkers. The company's headquarters in Cambridge, MA, and additional operations in Paris, France, Hong Kong, Shanghai, and Hangzhou, China position it as a global player in the biopharma, biotechnology, and pharmaceutical industries. Founded in 2013, HiFiBiO recently secured a significant $75.00M Series D investment on June 14, 2021. Notable investors in this round include B Capital Group, IDG Capital, Legend Star, Maison Capital, Mirae Asset Capital, Sequoia China, Sherpa Venture Capital, Hengxu Capital, Grand Mount Capital, and the Hong Kong Science and Technology Parks Corporation. The company has also established partnerships with major multinational pharmaceutical and biotech firms, further demonstrating the industry's confidence in HiFiBiO's innovative approach. With a robust clinical pipeline and strong financial backing, HiFiBiO Therapeutics is poised to continue its impactful contributions to the field of immunotherapies.